Valeant names CFO
MISSISSAUGA, Ontario — A former Goldman Sachs executive will join Valeant Pharmaceuticals as EVP and CFO.
Howard Schiller will take over the position from Philip Loberg, who has been serving as Valeant’s interim CFO on Dec. 1. Prior to his new role, Schiller was COO for Goldman Sachs’ investment banking division until his retirement in January.
"The board of directors and I are delighted that Howard has agreed to join our company," Valeant chairman and CEO J. Michael Pearson said. "Howard brings an unquestioned intellect, tremendous relevant experience, an impressive track record of success, and a humble demeanor which will fit well with our company. I also want to thank Phil for the role he has performed these past twelve months and I am pleased that he will continue to play a key role in our financial organization."
Genzyme names leaders of MS, rare diseases units
CAMBRIDGE, Mass. — Genzyme has named leaders of two units that are part of the core focus of the drug maker’s business.
Bill Sibold, former chief commercial officer at Avanir Pharmaceuticals, was appointed to serve as head of the multiple sclerosis business, while Rogério Vivaldi, who most recently served as president of Genzyme’s renal and endocrinology business, now is the head of the rare diseases business.
Both Sibold and Vivaldi will report to Genzyme president and CEO David Meeker, who recently became part of the company’s executive team.
“These appointments are a critical step in launching the new Genzyme,” Meeker said. “Bill and Rogério are dynamic leaders with the experience, energy, vision and commitment to patients needed to move us forward.”
Genzyme is a Sanofi company.
AstraZeneca, Targacept: TC-5214 ‘well-tolerated,’ did not meet endpoint in phase-3 trial
NEW YORK — AstraZeneca and Targacept released results of the first of four phase-3 clinical trials that investigated the efficacy and tolerability of a drug that could serve as an adjunct therapy to major depressive disorder patients that had an inadequate response to initial antidepressant therapies.
The drug makers said that while the drug was "well-tolerated" among study subjects, the study did not meet its primary endpoint of change after eight weeks of treatment with TC-5214, compared with placebo. The study was part of the Renaissance clinical trial program, which consists of four randomized, double-blind, placebo-controlled phase-3 studies and a fifth long-term safety study.
A new drug application for TC-5214 is expected to be filed in the United States during the second half of 2012.